Design of phase II ALS clinical trials

References

• Rothstein J., Jin L., Dykes‐Hoberg M., Kuncl R. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci 1993; 90: 6591–5
   PubMed Web of Science ®Google Scholar
• Traynor B., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S., et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006; 67: 20–7
   PubMed Web of Science ®Google Scholar
• Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772–5
   PubMed Web of Science ®Google Scholar
• Brown R. H Jr. Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell 1995; 80: 687–92
   PubMed Web of Science ®Google Scholar
• Tilley B. C., Palesch Y. Y., Kieburtz K., Ravina B., Huang P., Elm J. J., et al. Optimizing the ongoing search for new treatments for Parkinson's disease: using futility designs. Neurology 2006; 66: 628–33
   PubMedGoogle Scholar
• Palesch Y., Tilley B. An efficient multi‐stage, single‐arm phase II futility design for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))55–6
   PubMedGoogle Scholar
• Moore D., Miller R. Improving efficiency of ALS clinical trials using lead in designs. Amyotrophic Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))57–60
   PubMedGoogle Scholar
• Cheung Y., Gordon P., Levin B. Selecting promising ALS therapies in clinical trials. Neurology 2006; 67: 1748–51
   PubMed Web of Science ®Google Scholar
• Groeneveld G., Veldink J., van der Tweel I., Kalmijn S., Beijer C., de Visser M., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45
   PubMed Web of Science ®Google Scholar
• Whitehead J., Matsushita T. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Stat Med 2003; 22: 677–87
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. Statistical considerations for pilot studies. Int J Rad Oncol Biol Phys 1980; 6: 371–4
   PubMed Web of Science ®Google Scholar
• Cedarbaum J. The amyotrophic lateral sclerosis functional rating scale (ALSFRS). Archives of Neurology 1996; 53: 141–7
   PubMedGoogle Scholar
• Gehan E. Randomized or historical control groups in cancer clinical trials: are historical controls valid?. Journal of Clinical Oncology 1986; 47: 1024–5
   Google Scholar
• Byar D., Schoenfeld D., Green S., Amato D., Anderson J., Collins R., et al. Design considerations for AIDS trials. N Engl J Med 1990; 323: 1343–8
   PubMed Web of Science ®Google Scholar
• Cudkowicz M. E., Shefner J. M., Schoenfeld D. A., Zhang H., Andreasson K. I., Rothstein J. D., Drachman D. B. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology 2006; 60: 22–31
   PubMed Web of Science ®Google Scholar
• Cudkowicz M., Shefner J., Schoenfeld D., Brown R. J., Johnson H., Qureshi M., et al. A randomized, placebo‐controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003; 61: 456–64
   PubMed Web of Science ®Google Scholar
• Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., et al. A two‐stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66: 660–3
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. A simple algorithm for designing group sequential clinical trials. Biometrics 2001; 57: 972–4
   PubMedGoogle Scholar
• Whitehead J., Stratton I. Group sequential clinical trials with triangular continuation regions (Corr: V39 p1137). Biometrics 1983; 39: 227–36
   PubMed Web of Science ®Google Scholar
• Jennison C., Turnbull B. Group sequential methods with applications to clinical trials. CRC Press Inc., Boca Raton 2000
   Google Scholar
• Pocock S. When (not) to stop a clinical trial for benefit. JAMA 2005; 294: 2228–30
   PubMed Web of Science ®Google Scholar
• Schoenfeld D. Pro/con clinical debate: it is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: futility stopping can speed up the development of effective treatments. Critical Care 2005; 9: 34–6
   PubMedGoogle Scholar
• Spiessens B., Lesaffre E., Verbeke G. An overview of group sequential methods in longitudinal clinical trials. Statistical Methods in Medical Research 2000; 9: 497–515
   PubMedGoogle Scholar
• Cedarbaum J., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Traynor B., Zhang H., Shefner J., Schoenfeld D., Cudkowicz M. Functional outcome measures as clinical trial endpoints in amyotrophic lateral sclerosis. Neurology 2004; 63: 1933–5
   PubMed Web of Science ®Google Scholar
• Shefner J., Cudkowicz M., Brown R. A comparison of incremental with multipoint MUNE methods in transgenic ALS mice. Muscle and Nerve 2002; 25: 39–42
   PubMed Web of Science ®Google Scholar
• Shefner J. M., Cudkowicz M. E., Schoenfeld D., Conrad T., Taft J., Chilton M., et al. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• Lacomblez L., Bensimon G., Leigh P., Guillett P., Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Bensimon G., Lacomblez L., Meininger V., For the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Eng J Med 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar